Research programme: transforming growth factor beta-1 antagonists - GlaxoSmithKlineAlternative Names: SB 431542; SB 505124
Latest Information Update: 24 Jan 2008
At a glance
- Originator GlaxoSmithKline
- Class Benzamides; Dioxoles; Small molecules
- Mechanism of Action Transforming growth factor beta1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Wounds